TargetMol's 7 libraries for your research to combat against covid-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to a new evolutionary branch within the Coronaviruses (CoVs). The new emerging SARS-CoV-2 shares about 80% of the gene sequence of SARS-CoV; Proteins from SARS-CoV-2 and SARS-CoV were treated as homologous: identity value ≥ 65%. Therapeutics currently targeting spike RBD-ACE2, Nsp16, 3CLpro, PLpro, RdRp and X domain are possible treatments for SARS-CoV-2.
747 人阅读发布时间:2020-03-20 16:22